FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981631177> ?p ?o ?g. }

• W2981631177 endingPage "7576" @default.
• W2981631177 startingPage "7567" @default.
• W2981631177 abstract "Abstract Background Erythropoiesis‐stimulating agents effectively improve the hemoglobin levels in a fraction of anemic patients with myelodysplastic syndromes (MDS). Higher doses (HD) of recombinant human erythropoietin (rhEPO) have been proposed to overcome suboptimal response rates observed in MDS patients treated with lower “standard doses” (SD) of rhEPO. However, a direct comparison between the different doses of rhEPO is lacking. Methods A cohort of 104 MDS patients treated with HD was retrospectively compared to 208 patients treated with SD in a propensity score‐matched analysis to evaluate hematological improvement‐erythroid (HI‐E) rate induced by the different doses of rhEPO. The impact of rhEPO doses on survival and progression to leukemia was also investigated. Results Overall HI‐E rate was 52.6%. No difference was observed between different rhEPO doses ( P = .28) in matched cohorts; in a subgroup analysis, transfusion‐dependent patients and patients with higher IPSS‐R score obtained a higher HI‐E rate with HD, although without significant impact on overall survival (OS). Achievement of HI‐E resulted in superior OS. At univariate analysis, a higher HI‐E rate was observed in transfusion‐independent patients ( P < .001), with a lower IPSS‐R score ( P < .001) and lower serum EPO levels ( P = .027). Multivariate analysis confirmed that rhEPO doses were not significantly related to HI‐E ( P = .26). There was no significant difference in OS or progression to leukemia in patients treated with HD vs SD. Conclusion SD are substantially equally effective to HD to improve anemia and influencing survival in MDS patients stratified according to similar propensity to be exposed to rhEPO treatment." @default.
• W2981631177 created "2019-11-01" @default.
• W2981631177 creator A5000522683 @default.
• W2981631177 creator A5002823131 @default.
• W2981631177 creator A5003029538 @default.
• W2981631177 creator A5003509028 @default.
• W2981631177 creator A5006157396 @default.
• W2981631177 creator A5009267255 @default.
• W2981631177 creator A5011749918 @default.
• W2981631177 creator A5017850373 @default.
• W2981631177 creator A5018509851 @default.
• W2981631177 creator A5018772060 @default.
• W2981631177 creator A5025675788 @default.
• W2981631177 creator A5031590759 @default.
• W2981631177 creator A5031847692 @default.
• W2981631177 creator A5035304659 @default.
• W2981631177 creator A5035494273 @default.
• W2981631177 creator A5041417998 @default.
• W2981631177 creator A5044869604 @default.
• W2981631177 creator A5048224601 @default.
• W2981631177 creator A5057851384 @default.
• W2981631177 creator A5059985935 @default.
• W2981631177 creator A5069596141 @default.
• W2981631177 creator A5070851212 @default.
• W2981631177 creator A5072137633 @default.
• W2981631177 creator A5076114231 @default.
• W2981631177 creator A5078394069 @default.
• W2981631177 creator A5079420007 @default.
• W2981631177 creator A5084040459 @default.
• W2981631177 creator A5088023025 @default.
• W2981631177 creator A5088147792 @default.
• W2981631177 creator A5091318797 @default.
• W2981631177 date "2019-10-27" @default.
• W2981631177 modified "2023-10-18" @default.
• W2981631177 title "Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score‐matched analysis" @default.
• W2981631177 cites W187238933 @default.
• W2981631177 cites W1970566157 @default.
• W2981631177 cites W1978522934 @default.
• W2981631177 cites W1979340496 @default.
• W2981631177 cites W1979820704 @default.
• W2981631177 cites W2003948069 @default.
• W2981631177 cites W2004089260 @default.
• W2981631177 cites W2014217341 @default.
• W2981631177 cites W2014903824 @default.
• W2981631177 cites W2016579895 @default.
• W2981631177 cites W2029738096 @default.
• W2981631177 cites W2030094742 @default.
• W2981631177 cites W2034349976 @default.
• W2981631177 cites W2055719366 @default.
• W2981631177 cites W2071496654 @default.
• W2981631177 cites W2080361105 @default.
• W2981631177 cites W2129510594 @default.
• W2981631177 cites W2149982846 @default.
• W2981631177 cites W2155962669 @default.
• W2981631177 cites W2165036959 @default.
• W2981631177 cites W2168458505 @default.
• W2981631177 cites W2326726820 @default.
• W2981631177 cites W2341693682 @default.
• W2981631177 cites W2407022137 @default.
• W2981631177 cites W2412900863 @default.
• W2981631177 cites W2559601897 @default.
• W2981631177 cites W2560286007 @default.
• W2981631177 cites W2734059981 @default.
• W2981631177 cites W2794499016 @default.
• W2981631177 cites W2886715686 @default.
• W2981631177 cites W2904309298 @default.
• W2981631177 doi "https://doi.org/10.1002/cam4.2638" @default.
• W2981631177 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6912022" @default.
• W2981631177 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31657156" @default.
• W2981631177 hasPublicationYear "2019" @default.
• W2981631177 type Work @default.
• W2981631177 sameAs 2981631177 @default.
• W2981631177 citedByCount "4" @default.
• W2981631177 countsByYear W29816311772020 @default.
• W2981631177 countsByYear W29816311772022 @default.
• W2981631177 countsByYear W29816311772023 @default.
• W2981631177 crossrefType "journal-article" @default.
• W2981631177 hasAuthorship W2981631177A5000522683 @default.
• W2981631177 hasAuthorship W2981631177A5002823131 @default.
• W2981631177 hasAuthorship W2981631177A5003029538 @default.
• W2981631177 hasAuthorship W2981631177A5003509028 @default.
• W2981631177 hasAuthorship W2981631177A5006157396 @default.
• W2981631177 hasAuthorship W2981631177A5009267255 @default.
• W2981631177 hasAuthorship W2981631177A5011749918 @default.
• W2981631177 hasAuthorship W2981631177A5017850373 @default.
• W2981631177 hasAuthorship W2981631177A5018509851 @default.
• W2981631177 hasAuthorship W2981631177A5018772060 @default.
• W2981631177 hasAuthorship W2981631177A5025675788 @default.
• W2981631177 hasAuthorship W2981631177A5031590759 @default.
• W2981631177 hasAuthorship W2981631177A5031847692 @default.
• W2981631177 hasAuthorship W2981631177A5035304659 @default.
• W2981631177 hasAuthorship W2981631177A5035494273 @default.
• W2981631177 hasAuthorship W2981631177A5041417998 @default.
• W2981631177 hasAuthorship W2981631177A5044869604 @default.
• W2981631177 hasAuthorship W2981631177A5048224601 @default.
• W2981631177 hasAuthorship W2981631177A5057851384 @default.
• W2981631177 hasAuthorship W2981631177A5059985935 @default.
• W2981631177 hasAuthorship W2981631177A5069596141 @default.

• next